Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
马萨诸塞州沃尔瑟姆，2024年11月12日（环球新闻社）- Apellis Pharmaceuticals，Inc.（纳斯达克：APLS）宣布本公司将于2024年11月19日周二上午8:30在伦敦杰弗里斯医疗保健大会上举行网络交流。
The live conference webcast will be posted on the "Events and Presentations" page of the "Investors and Media" section of the company's website. A replay of the webcast will be available for approximately 90 days following the event.
现场会议网络直播将发布在公司网站“投资者和媒体”部门的“事件和演示”页面上。网络直播重播将在活动结束后约90天内提供。
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit or follow us on Twitter and LinkedIn.
关于Apellis
Apellis Pharmaceuticals是一家全球生物制药公司，结合勇敢的科学和同情心，为一些最具挑战性的疾病患者开发改变生命的治疗方案。我们推出了15年来第一个新的补体药物系，现有两种针对C3的批准药物，其中包括全球首款用于地理萎缩症的治疗。我们相信，我们才刚刚开始释放针对C3治疗严重眼部、罕见和神经系统疾病的潜力。欲了解更多信息，请访问或关注我们的Twitter和LinkedIn。
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
投资者联系：
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
